In patients with stage III colorectal cancers who participated in the NCCTG N0147 trial, event-free survival (EFS) of the group with BRAF mutations and MMR deficiency was similar to cancers with MMR proficiency and no BRAF or KRAS mutations, while EFS of proficient for MMR cancers with BRAF mutations was inferior [35]. This evidence concerns the gene KRAS and colorectal cancer.